Raymond James & Associates Crinetics Pharmaceuticals, Inc. Call Options Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRNX
# of Institutions
242Shares Held
79.6MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$363 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$359 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$339 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$285 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$257 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $3.1B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...